If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar revenue growth and a young biotech that recently proved the strength of its ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s collaboration with Sirius on FXI siRNA SRSD107, BMO Capital reaffirmed ...

The Global Biotechnology Market is projected to surge from US$ 4.26 trillion in 2024 to US$ 1.40 trillion by 2033, with a robust CAGR of 13.1%. This growth is driven by advances in genetic engineering ...

Cathie Wood is having a good year. The Ark Invest founder, CEO, and ace stock picker isn't back to her peak 2020 form when many of her exchange-traded funds (ETFs) more than doubled in value. However, ...

The provider of gene-editing technology employs ten staff and plans to double its team within the next two years ...

A University of Nottingham spinout that has developed a novel gene-editing tool has raised £2m from the Midlands Engine Investment Fund II.

CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...

CureVac's (CVAC) mRNA innovations, strong patent portfolio, and investment potential. Learn the risks and rewards of this biotech stock.

Jefferies analyst Greg Konrad raised the firm’s price target on AeroVironment (AVAV) to $365 from $320 and keeps a Buy rating on the shares after ...

Dublin-based Aerska launched on Wednesday with $21 million in seed funding and a technology designed to shuttle RNA interference medicines past the blood-brain barrier.

This is not a call to despair. It's a call to coherence. To demand that the best of times be extended beyond the operating room and into the public square. To insist that the same brilliance we apply ...